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(Sigma–Aldrich, St. Louis, MO), anti-α-SMA (AnaSpec, Fremont,
CA), anti-PAR-1 (Santa Cruz, Delaware Avenue, CA), anti-PAR-2
(Santa Cruz, Delaware Avenue, CA), anti-PAR-3 (Santa Cruz, Dela-
ware Avenue, CA) and anti-PAR-4 (Santa Cruz, Delaware Avenue,
CA) as the primary antibodies.
Atrial ﬁbroblasts were cultured to form a monolayer on 24-well
tissue culture plates (FALCON; Becton Dickinson Labware). The
cells were mechanically “wounded” and treated with FXa with orWe have recently found the co-localization of protease activated
receptor (PAR)-1 with α-smooth muscle actin (α-SMA) in the subendo-
cardial space from autopsied hearts of human [1]. α-SMA is activated by
factor Xa (FXa) via PAR-1 in the human andmurine ﬁbroblasts [2]. How-
ever, there are four types of PARs; PAR-1, -2, -3 and -4 [3]; and little is
knownaboutwhether the PAR-2, -3 and -4 are associatedwithpromoting
ﬁbrosis. In this study, we examined which types of PARs accelerate the
pro-ﬁbrotic activity of cultured neonatal rat atrial ﬁbroblasts.
FXa from human plasma was purchased from Haematologic
Tehnologies (River Road, VT). Rivaroxaban was provided from Bayer
Pharma AG (Leverkusen, Germany). We purchased SFLLR-NH2 (Sigma–
Aldrich, St. Louis, MO), SLIGRL-NH2 (Sigma–Aldrich, St. Louis, MO),
SFNGGP-NH2 (Ana Spec, Fremont, CA), AYPGKF (Ana Spec, Fremont,
CA), FR171113 (TOCRIS bioscience, Bristol, United Kingdom).
All animals received humane care and study protocols comply with
the guidelines of the Animal Research Committee at Jikei University
School of Medicine. Primary atrial ﬁbroblast cultures were prepared
from four-day-old Sprague–Dawley rat heart atria using the Neonatal
Cardiomyocyte Isolation System with a differential plating procedure.
Theﬁbroblastswere cultured inDMEM/10% fetal bovine serum andhar-
vested on days 3–4 of the primary culture.81 3 3459 6043.
land Ltd. Open access under CC BY-NC-SAwithout FR171113 (3 μM). After 24 h of incubation, the ﬁbroblasts
were washed with PBS. Photographs were taken at 40× magniﬁca-
tion. The migration rate was calculated by counting the cells that
crossed into the “scratch” (wounded) area, and the values were pre-
sented as a percentage of the total cells on identical “non-scratched”
areas (100%).
Continuous variables are expressed as the means ± standard error
of the mean (SEM). All statistical analyses were performed using the
SPSS software program (version 11.5 J, SPSS Japan Inc., Tokyo, Japan),
and differences were considered to be statistically signiﬁcant for values
of p b 0.05. All data were analyzed usingWelch statistics with post-hoc
testing.
We examined the existence of PAR-1, 2, 3 and 4 in the ﬁbroblasts by
Western blot analysis (Fig. 1a). All PARs have been demonstrated by
Western blot analysis.
We examined theα-SMA expression in atrial ﬁbroblasts (Fig. 1b), and
found that FXa (50 nM) signiﬁcantly increased the α-SMA expression
levels, which was signiﬁcantly inhibited by treatment with the direct
FXa inhibitor rivaroxaban (10 μM) (p b 0.01). The PAR-1 agonist peptide,
SFLLR-NH2 (100 μM) also increased the expression of α-SMA (Fig. 1b).
However, SLIGRL (100 μM), AYPGKF (100 μM) and AYPGKF (100 -
μM) + SFNGGP (100 μM) did not increase the expression of α-SMA
(Fig. 1c). We have next used PAR-1 antagonist peptide, FR171113 and
stimulated ﬁbroblast with FXa (Fig. 2a). The increase of the expression
of α-SMA by FXa was inhibited by FR171113.
We observed that the ﬁbroblasts stimulated with FXa (50nM)
migrated more extensively than the control ﬁbroblasts. This migra-
tion was signiﬁcantly inhibited by treatment with FR171113
(Fig. 2b).
We have found that FXa activates proliferation of neonatal rat atrial ﬁ-
broblasts. PAR-2 agonist peptide, SLIGRL-NH2 could not activate PAR-2. license.
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Fig. 1. a. The results of Western blot analysis show PAR-1, -2, -3 and -4 expressions. b. The results of the Western blot analysis showing theαSMA expression in neonatal rat atrial ﬁbro-
blasts stimulated with FXa (n = 4). #: p b 0.01, N.S.: not signiﬁcant, PAR-1: SFLLR-NH2 (100 μM), R: rivaroxaban. c. The results of the Western blot analysis show the αSMA expression
stimulated with SLIGRL-NH2 (100 μM), AYPGKF-NH2 (100 μM), AYPGKF-NH2 (100 μM) + SFNGGP-NH2 (100 μM) (n = 4). N.S.: not signiﬁcant.
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Fig. 2. a. The results of theWestern blot analysis show theαSMA expression in neonatal rat atrial ﬁbroblasts (n = 5). #: p b 0.01, N.S.: not signiﬁcant. b. The results of the cell migration
wound healing “scratch” assay (n = 4). ✻: p b 0.05, N.S.: not signiﬁcant.
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this study, PAR-3 agonist peptide SFNGGP and PAR-4 agonist pep-
tide AYPGKF did not show the pro-ﬁbrotic effects in the
ﬁbroblasts.
PAR-1 may be related to the pathogenesis of atrial ﬁbrosis [1].
But other PARs (PAR-2, -3 and -4) are little known in the view
point of atrial ﬁbrosis. The present study highlights that the rat
atrial ﬁbrosis is mainly played by the PAR-1 but not PAR-2, -3
and -4.References
[1] Ito K, Date T, IkegamiM, Hongo K, Fujisaki M, Katoh D, et al. An immunohistochemical
analysis of tissue thrombin expression in the human atria. PLoS One 2013;8:e65817.
[2] Scotton CJ, Krupiczojc MA, Königshoff M, Mercer PF, Lee YC, Kaminski N, et al.
Increased local expression of coagulation factor X contributes to the ﬁbrotic response
in human and murine lung injury. J Clin Invest 2009;119:2550–63.
[3] Macfarlane SR, Seatter MJ, Kanke N, Hunter GD, Plevin R. Proteinase-activated recep-
tors. Pharmacol Rev 2001;53:245–82.
[4] Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR.
PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000;404:609–13.
